… An initial phase I study of STI571 included 83 Ph + CML patients who had failed interferon-…
83 Ph + CML patients who had failed interferon-based therapy. Patients were required to be …

… issue in patients with chronic myeloid leukemia (CML) treated … in patients receiving second-
or third-generation BCR/ABL1 TKIs. Such VAEs include pulmonary hypertension in patients …

… In patients with CP-CML, developing a BCR-ABL mutation on imatinib is associated with a
… Overall, these data highlight that evaluating patients for BCRABL mutations is an important …

… -treated patients to determine whether patients … patients with BCR-ABL1 ≤10% at 3 months
(P < .001). However, the poorest outcomes among the 95 evaluable patients with BCR-ABL1 …

… 19 of 21 CML patients contain one or both of two alternative bcr-abl RNA junctions transcribed
from the chimeric bcr-abl gene formed on the Ph 1 -chromosome. In two patients with the …

… in a proportion of patients receiving imatinib monotherapy, mainly in patients with advanced-…
patients suffering from all stages of Philadelphia (Ph) and/or BCR-ABL–positive CML and …

… of patients due to age of the patient and donor availability. Interferon-α constitutes a second
therapeutic option for CML patients, and … in 10–20% of CML patients. At the molecular level, …

… (CML). Present in 95% of patients with CML, Bcr-Abl has been demonstrated to be a …
oncogene in animal studies and is considered the causative molecular abnormality of CML. …

… for measuring BCR-ABL transcripts in patients with CML … laboratories can express BCR-ABL
transcript levels on an … ) for the BCR-ABL gene to monitor individual patients responding to …

… performed for 26 patients showed that the breakpoints of eight of the nine patients in blast
crisis were in the 3′ portion of the bcr, whereas the breakpoints in the 17 patients in the …